Not yet, but Bausch + Lomb and Novaliq just submitted an NDA for the investigational dry eye treatment, NOV03 (perfluorohexyloctane).
What is NOV03?
NOV03 is a preservative-free, investigational eye drop developed to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.
It works by stabilizing the lipid layer to prevent aqueous evaporation and by penetrating the meibomian glands, where it has been reported to interact with and dissolve the altered, viscous meibum in the glands.
When might we be able to prescribe this drop?
Maybe next year. A Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023, has been assigned to NOV03. (via)